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Polycythemia vera (PV) and essential thrombocythemia (ET) 
are myeloproliferative neoplasms (MPN) that can progress to 
post‐PV (PPV) myelofibrosis (MF) and post‐ET (PET) MF 
(from now on referred to as secondary myelofibrosis—SMF) 
with a progressive clinical phenotype.1 Among 20,250 MPN 
patients included in the Surveillance, Epidemiology, and End 
Results Program (SEER) database,2 the 10‐year cumulative 
incidence of nonhematological second primary malignancies 
(SPM) was 12.7%, significantly higher than that expected in 
the general US population. Information on development of 
SPM in SMF is scant.
Objectives of this study are to establish SPM incidence 
in SMF, to investigate potential relationship between SPM 
and SMF occurrence in PV and ET, and to address poten-
tial effect of JAK inhibitors (JAKi) on SPM occurrence in 
SMF. For these purposes, we evaluated the MYSEC cohort 
3 of 781 SMF and the Pavia cohort of 611 PV and 841 ET 
patients not evolved into SMF during a median follow up 
of 4.6 years (range, 0.1‐39.7). PV, ET, and SMF diagno-
ses were reviewed according to the WHO and the IWG‐
MRT criteria, respectively. The study was approved by 
the Review Board of each Institution and conducted in ac-
cordance with the Declaration of Helsinki. We performed 
time‐to‐event analysis with Cox regression models. Pre‐ 
and post‐SMF periods were treated considering SMF as a 
time‐dependent state. Likewise, JAKi treatment was con-
sidered a time‐dependent covariate present from the date of 
drug start. We defined SPM all malignancies except myelo-
dysplastic syndromes, acute leukemias, carcinomas in situ, 
breast fibroadenomas, superficial bladder carcinomas, and 
nonmelanoma skin cancers (NMSC). SPM* included SPM 
and NMSC.
In the MYSEC cohort, within a median follow‐up of 
14.8 years (range, 0.9‐46) from PV/ET diagnosis, 55 patients 
(7%) developed SPM. Among these, eight did not have the 
SPM date available and were excluded from the time‐depen-
dent analysis. Twenty‐two (46.8%) developed a SPM during 
the ET/PV phase and 25 (53.2%) after SMF transformation. 
SPM subtypes are described in Figure 1.
The incidence of SPM after SMF diagnosis was 0.98/100 
patient‐years. There was a trend of association between male 
gender and SPM occurrence (P = 0.055). No statistically sig-
nificant differences in clinical presentation, driver mutations, 
karyotype, bone marrow fibrosis, and MYSEC‐PM strata at 
the time of SMF diagnosis were found within SMF patients 
with and without SPM.
When including NMSC (SPM* group), we found 77 
(9.9%) cases, 67 of them with date of diagnosis available: 26 
(38.8%) during the ET/PV phase and 41 (61.2%) after SMF 
transformation. The incidence of SPM* after SMF diagno-
sis was 1.56/100 patient‐years. No significant differences in 
terms of clinical phenotype and genotype were found within 
SMF patients with and without SPM*.
Merging the MYSEC and the Pavia cohorts allowed us 
to evaluate the impact of SMF transformation on the SPM 
occurrence (treated as time‐dependent variable) in PV and 
ET. The incidence of SPM resulted not significantly different 
between patients who evolved into SMF (MYSEC cohort) 
and those who did not (Pavia cohort) (P = 0.06, Figure 2A). 
Conversely, the incidence of SPM* was significantly higher 
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Abstract
Patients with myeloproliferative neoplasms (MPN) are known to have higher inci-
dence of nonhematological second primary malignancies (SPM) compared to general 
population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the 
incidence of SPM after SMF diagnosis resulted 0.98/100 patient‐years. When includ-
ing non‐melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patient‐
years. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. 
Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving 
into SMF. In this subanalysis, we did not find any correlation between SPM and SMF 
occurrence. These findings highlight the need of studies aimed at identifying MPN 
patients at higher risk of SPM.
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in patients who evolved into SMF (P = 0.002, Figure 2B), 
also when adjusted for age at the time of PV/ET (HR: 1.56, 
95%CI: 1.0‐2.4; P = 0.04).
Finally, we assessed the effect of JAKi treatment on the 
occurrence of SPM in 151 patients of the MYSEC database: 
111 received ruxolitinib, 10 fedratinib, 11 momelotinib, 
one XL019, and 18 a JAKi sequence. Overall, four patients 
(2.6%) developed SPM (all treated during SMF phase) within 
a median time of JAKi exposure of 1.2 years (range, 0.2‐2.2): 
one case each of renal, liver, rectal, and pancreatic cancer. 
We did not find any correlation between JAKi (treated as 
time‐dependent variable) and occurrence of SPM (log‐rank 
P = 0.34). Of interest, none of the two SMF who had lym-
phomas had been treated with JAKi. On the other hand, on 
extending the analysis to SPM*, eight cases (5.3%) were di-
agnosed. We found a significant correlation between JAKi 
and occurrence of SPM* in SMF (P = 0.02). This was con-
firmed even adjusting for the SMF subtype and for age at 
SMF diagnosis (HR: 2.4; 95% CI: 1.1‐5.4; P = 0.03).
A clear correlation between cytotoxic treatments and SPM 
occurrence has never been clearly demonstrated in MPN. 
Hydroxyurea treatment is associated with skin damage and 
with NMSC. However, a recent study reported a significantly 
higher number of SPM in MPN patients who had received no 
prior therapy, as compared with patients who received mono-
therapy or multiple therapies.4 The wide use of JAKi and 
their effect on immunity control has raised the issue of SPM 
in patients under treatment. A higher incidence of NMSC has 
been documented in PV receiving ruxolitinib (especially in 
those who received hydroxyurea first).5 Our data confirm this 
relationship highlighting the need for treating physicians to 
monitor cutaneous cancers before and during JAKi. We did 
not find any lymphoma in our cohort of 151 JAKi‐treated 
patients, differently from a recent report on 69 patients, how-
ever, with a longer 25‐month JAKi exposure.6
In conclusion, this study provides evidence that in PPV and 
PET MF the incidence of SPM and SPM* is about 1.0 and 
1.5/100 patient‐years, respectively. There was no evidence of 
F I G U R E  1  Distribution of secondary 
primary malignancies (SPM) in the MYSEC 
cohort
F I G U R E  2  Cumulative incidence of second primary malignancies in patients with essential thrombocythemia (ET) and polycythemia vera 
(PV) with or without transformation into secondary myelofibrosis (SMF). Data are from 2233 patients with PV and ET, excluding (A) or including 
(B) nonmelanoma skin cancers 
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association between JAKi treatment and SPM development, with 
the exception of NMSC occurrence. Finally, we showed that in 
patients with PV or ET the occurrence of SMF is not associated 
with that of SPM, leaving the two events pathogenetically inde-
pendent. The higher occurrence of NMSC we found is probably 
related to the use of hydroxyurea first or JAKi in the last times. 
These findings highlight the need of studies aimed at identifying 
patients at higher risk of second primary malignancies.
ORCID
Rami Komrokji  https://orcid.org/0000-0002-1876-5269 
Marco Ruggeri  https://orcid.org/0000-0003-1557-0957 
Francesco Albano  https://orcid.org/0000-0001-7926-6052 
Tiziano Barbui  https://orcid.org/0000-0003-2747-6327 
Toni Giorgino  https://orcid.org/0000-0001-6449-0596 
Francesco Passamonti  https://orcid.
org/0000-0001-8068-5289 
REFERENCES
 1. Mora B, Giorgino T, Guglielmelli P, et al. Phenotype variability of 
patients with post polycythemia vera and post essential thrombo-
cythemia myelofibrosis is associated with the time to progression 
from polycythemia vera and essential thrombocythemia. Leuk Res. 
2018;69:100‐102.
 2. Brunner AM, Hobbs G, Jalbut MM, et al. A population‐based 
analysis of second malignancies among patients with myelop-
roliferative neoplasms in the SEER database. Leuk Lymphoma. 
2016;57:1197‐1200.
 3. Passamonti F, Giorgino T, Mora B, et al. A clinical‐molecular prog-
nostic model to predict survival in patients with post polycythemia 
vera and post essential thrombocythemia myelofibrosis. Leukemia. 
2017;12:2726‐2731.
 4. Masarova L, Cherry M, Newberry KJ, et al. Secondary solid tu-
mors and lymphoma in patients with essential thrombocythemia 
and polycythemia vera – single center experience. Leuk Lymphoma. 
2016;57:237‐239.
 5. Griesshammer M, Saydam G, Palandri F, et al. Ruxolitinib for the 
treatment of inadequately controlled polycythemia vera without 
splenomegaly: 80‐week follow‐up from the RESPONSE‐2 trial. Ann 
Hematol. 2018;97:1591‐1600.
 6. Porpaczy E, Tripolt S, Hoelbl‐Kovacic A, et al. Aggressive B‐cell 
lymphomas in patients with myelofibrosis receiving JAK1/2 inhibi-
tor therapy. Blood. 2018;132:694‐706.
How to cite this article: Mora B, Rumi E, Guglielmelli 
P, et al. Second primary malignancies in 
postpolycythemia vera and postessential 
thrombocythemia myelofibrosis: A study on 2233 
patients. Cancer Med. 2019;8:4089–4092. https://doi.
org/10.1002/cam4.2107
